New insider activity at Conmed ( (CNMD) ) has taken place on September 15, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Director Charles Farkas recently sold 2,000 shares of Conmed stock, amounting to a total transaction value of $107,042.
Recent Updates on CNMD stock
Conmed Corporation has recently made significant developments that could impact its stock performance. The company announced the appointment of Kim Kelderman to its Board of Directors, bringing his extensive life sciences experience to enhance strategic initiatives and long-term vision. Additionally, Conmed is conducting a clinical study on the BioBrace® Reinforced Implant for ACL reconstruction, which aims to improve surgical outcomes. This study could boost investor confidence and stock performance if successful, as it may demonstrate enhanced effectiveness in orthopedic procedures. These developments, along with Conmed’s strong financial performance and strategic initiatives, contribute to a positive outlook for the company’s growth potential.
Spark’s Take on CNMD Stock
According to Spark, TipRanks’ AI Analyst, CNMD is a Outperform.
Conmed’s overall stock score of 74 reflects its strong financial performance and positive earnings call insights, which are slightly offset by neutral technical indicators and a balanced valuation. The company’s growth trajectory and strategic initiatives in the medical devices industry position it well for future expansion.
To see Spark’s full report on CNMD stock, click here.
More about Conmed
YTD Price Performance: -22.16%
Average Trading Volume: 460,871
Technical Sentiment Signal: Sell
Current Market Cap: $1.64B